title: [Connective tissue diseases: news in therapy, role of biologics agents].
abstract: Systemic lupus erythematosus and primary Sjögren's syndrom are the two major connective tissue diseases. A better knowledge of their physiopathology allows us today to propose an adapted therapy. Moreover progress concerns the oldest treatment, hydroxychloroquine, and biotherapy. Hydroxychloroquine is still an actual treatment for lupus, its positive effects are better understood today. Nevertheless it does not seem to be efficient to treat primitive Sjögren. Biotherapy targeting B lymphocytes seems efficient in these two connective tissue diseases. Anti TNF therapy is not recommended and seems to induce connective tissue diseases. The real news is the recent approval and reimbursement in Switzerland of the new drug belimumab (Benlysta) in case of moderate lupus.
authors.affiliation: Service de rhumatologie et Centre des maladies osseuses, Departement de I'appareil locomoteur, Hôpital orthopédique, CHUV, 1005 Lausanne. berengere.aubry@chuv.ch
authors.forename: B
authors.initials: B
authors.lastname: Aubry-Rozier
authors.forename: I
authors.initials: I
authors.lastname: Fabreguet
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001402:B-Lymphocytes / Q000378:metabolism; D003240:Connective Tissue Diseases / Q000188:drug therapy* / Q000503:physiopathology; D017277:Drug Approval; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D013557:Switzerland
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D006886:Hydroxychloroquine; C511911:belimumab